At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
BMS-986205 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated
In Brief
A Phase 3 clinical trial evaluating BMS-986205, Nivolumab, and 1 other intervention for Melanoma and Skin Cancer. Completed, enrolled 20 participants across 63 sites in 16 countries.
Detailed Summary
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Skin Cancer
CountriesAustralia, Canada, Czechia, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, New Zealand, Poland, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionJul 2020
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 30, 2017
Primary CompletionJul 2, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.7 years ago
Interventions
BMS-986205drug
specified dose on specified day
Nivolumabbiological
Specified dose on specified day
Placebodrug
Specified dose on specified day